Breast cancer is the most common malignant tumor in women globally. Currently, due to limited data, there are no international guidelines for addressing the management of a large group of patients during infectious disease pandemics. Coronavirus disease 2019 (COVID-19), declared as a pandemic by the World Health Organization (WHO), has rapidly spread globally. The COVID-19 pandemic changed our daily routines and forced us to rethink the management of breast cancer patients. Clinicians need to take into account multiple factors such as the timing and delivery of cancer care, epidemic prevention and control, and the allocation of medical resources. Determining ways to reasonably adjust the treatment strategy is a real challenge. In this review, we aim to discuss particular challenges associated with managing breast cancer patients during the COVID-19 pandemic, share experience from Chinese oncologists and surgeons and propose some practical approaches to the management of early-stage breast cancer patients from a surgical standpoint.
【저자키워드】 COVID-19, surgical treatment, adjuvant therapy, Treatment delay, neoadjuvant therapy, Early-stage breast cancer, 【초록키워드】 Treatment, Coronavirus disease 2019, pandemic, COVID-19 pandemic, Cancer, surgical, Infectious disease, Spread, Epidemic, Breast, management, International, Patient, Pandemics, WHO, women, Care, World Health Organization, Factor, Medical resources, surgeon, Chinese, breast cancer patients, malignant tumor, approach, breast cancer patient, oncologist, changed, Determining, adjust, the timing, 【제목키워드】 coronavirus disease, surgical, China, breast cancer patient,